兆科眼科-B(06622) - 2023 - 年度财报

• NVK002: Successful completion of Phase III Mini-CHAMP In January 2023 we announced that CsA, an innovative gel we are developing to treat DED, had passed on-site regulatory and clinical trial inspections and GMP review. As described above, we later took the decision to temporarily withdraw the NDA in order to make some adjustments and address questions that surfaced during the CDE review process. We plan to re-file an updated submission later this year. Simultaneously, we continued our efforts to explore ...